ArticleCancer immunology, immunotherapy : CII2009
Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 95 citations in OpenAlex.
- Immunological Insights into Photodynamic Therapy of Glioblastoma Multiforme.Molecules (Basel, Switzerland) · 2025Review
- Self-Applied Daylight Photodynamic Therapy: A Paradigm Shift?International journal of molecular sciences · 2025Review
- Antitumor Immunity Mediated by Photodynamic Therapy Using Injectable Chitosan Hydrogels for Intratumoral and Sustained Drug Delivery.Biomacromolecules · 2024Article
- Overcoming Barriers in Photodynamic Therapy Harnessing Nanogenerators Strategies.International journal of biological sciences · 2024Review
- Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model.Frontiers in oncology · 2024Article
- The impact of photodynamic therapy on immune system in cancer - an update.Frontiers in immunology · 2024Review
- Application of Different Wavelengths of LED Lights in Antimicrobial Photodynamic Therapy for the Treatment of Periodontal Disease.Antibiotics (Basel, Switzerland) · 2023Review
- Photodynamic Therapy for Colorectal Cancer: An Update and a Look to the Future.International journal of molecular sciences · 2023Review
- Current Challenges and Opportunities of Photodynamic Therapy against Cancer.Pharmaceutics · 2023Review
- Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.Oncoimmunology · 2023Article
- Research Progress of Conjugated Nanomedicine for Cancer Treatment.Pharmaceutics · 2022Review
- Article
- Article
- The Role of Photodynamic Therapy in Triggering Cell Death and Facilitating Antitumor Immunology.Frontiers in oncology · 2022Review
- The Immunogenetic Aspects of Photodynamic Therapy.Advances in experimental medicine and biology · 2022Article
- Multifunctional Nanosystems Powered Photodynamic Immunotherapy.Frontiers in pharmacology · 2022Review
- Enhancement of innate and adaptive anti-tumor immunity by serum obtained from vascular photodynamic therapy-cured BALB/c mouse.Cancer immunology, immunotherapy : CII · 2021Article
- Repeated porphyrin lipoprotein-based photodynamic therapy controls distant disease in mouse mesothelioma via the abscopal effect.Nanophotonics (Berlin, Germany) · 2021Article
- Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.British journal of cancer · 2021Article
- Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular-targeted photodynamic therapy (VTP) takes advantage of intravascular excitation of a photosensitizer (PS) to produce cytotoxic reactive oxygen species (ROS). These ROS are potent mediators of vascular damage inducing rapid local thrombus formation, vascular occlusion, and tissue hypoxia. This light-controlled process is used for the eradication of solid tumors with Pd-bacteriochlorophyll derivatives (Bchl) as PS. Unlike classical photodynamic therapy (PDT), cancer cells are not the primary target for VTP but instead are destroyed by treatment-induced oxygen deprivation. VTP initiates acute local inflammation inside the illuminated area accompanied by massive tumor tissue death. Consequently, in the present study, we addressed the possibility of immune response induction by the treatment that may be considered as an integral part of the mechanism of VTP-mediated tumor eradication. The effect of VTP on the host immune system was investigated using WST11, which is now in phase II clinical trials for age-related macular degeneration and intended to be evaluated for cancer therapy. We found that a functional immune system is essential for successful VTP. Long-lasting systemic antitumor immunity was induced by VTP involving both cellular and humoral components. The antitumor effect was cross-protective against mismatched tumors, suggesting VTP-mediated production of overlapping tumor antigens, possibly from endothelial origin. Based on our findings we suggest that local VTP might be utilized in combination with other anticancer therapies (e.g., immunotherapy) for the enhancement of host antitumor immunity in the treatment of both local and disseminated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.